Latest Intelligence on Pharmaceuticals and Healthcare in Middle East and Africa

Published within

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Cervical cancer: vaccines set to drastically reduce incidence

Despite a significant drop in the incidence of cervical cancer in the western world due to routine screening, cervical cancer remains the second most common cancer in women the world over. However, two new vaccines for the human papilloma virus (HPV), a major risk factor for cervical cancer, are set to have a dramatic impact on the incidence of cervical cancer all over the globe.

Published By Datamonitor
19 Mar 2007
Expert View
Expert View

The pharmaceutical industry: key strategies for challenging times

With declining returns from drug development pipelines and generic erosion of drug market shares, it is a very challenging time to be in the drug manufacturing business. However, with the increasing levels of M&A and licensing activity, the big players are still able to get access to novel drugs without all the draining costs of research and development.

Published By Datamonitor
21 Mar 2007
ResearchWire
ResearchWire

Lung cancer market: opportunities exist for targeting rarer tumor types

Published By Datamonitor
28 Mar 2007
Expert View
Expert View

Migraine market: Trexima approval delays benefits generic triptan

Estimated to be worth $3.4 billion in 2005, the migraine market is entering a state of maturity driven by the dominance of the triptan class of drugs. The ongoing approval delays with GlaxoSmithKline and Pozen's Trexima, coupled with triptan genericization, will result in the migraine market value decreasing by 20% from 2008 to $3.2 billion in 2015.

Published By Datamonitor
29 Mar 2007
ResearchWire
ResearchWire

Major depressive disorder: potential high sales for GSK's pipeline drug

Published By Datamonitor
02 Apr 2007
ResearchWire
ResearchWire

Hospital acquired infections: crucial need for gram-negative antibacterials

Published By Datamonitor
11 Apr 2007
Expert View
Expert View

Changing of the guard in HIV treatment

The HIV market is forecast to grow from $7.1 billion in 2005 to an estimated $10.6 billion in 2015. This growth is to be driven by a combination of several factors, including an increase in the number of people diagnosed, and the launch of several new drugs and drug classes which offer new hope to patients who otherwise would have at-best limited, but perhaps no therapeutic options left at all.

Published By Datamonitor
12 Apr 2007
ResearchWire
ResearchWire

Multiple sclerosis: novel therapies set to increase market value

Published By Datamonitor
16 Apr 2007
Expert View
Expert View

RSV: lack of vaccine puts most vulnerable at risk

An infection with the respiratory syncytial virus can result in hospitalization and sometimes respiratory failure. With no suitable treatment available and the only preventative medication considered too expensive to be widely prescribed, the need for an effective vaccine is high. However, given the failure of recent developmental efforts the launch of a successful vaccine is still some time away.

Published By Datamonitor
18 Apr 2007
Expert View
Expert View

Teammates as well as targets: rethinking pharmaceutical eStrategy

The internet is potentially a powerful tool for pharmaceutical companies to inform patients and prescribers alike of their products, yet few companies achieved the expected return on their initial investments. However, there are still compelling reasons for companies to move forward with an eStrategy - provided that the pharmaceutical industry is willing to rethink its approach.

Published By Datamonitor
19 Apr 2007

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

No help is available.